中国晚期乳腺癌临床诊疗专家共识(2018版)

2018-10-16 中国抗癌协会乳腺癌专业委员会 中华肿瘤杂志.2018,40(9):703-713.

乳腺癌是全球女性最常见的恶性肿瘤,2015 年中国新发乳腺癌病例约27.2 万,死亡约7 万余例。在每年新发乳腺癌病例中,约3% ~ 10%的妇女在确诊时即有远处转移。早期患者中,30%~40%可发展为晚期乳腺癌,5 年生存率仅20%,总体中位生存时间为2~3 年。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时

中文标题:

中国晚期乳腺癌临床诊疗专家共识(2018版)

发布日期:

2018-10-16

简要介绍:

乳腺癌是全球女性最常见的恶性肿瘤,2015 年中国新发乳腺癌病例约27.2 万,死亡约7 万余例。在每年新发乳腺癌病例中,约3% ~ 10%的妇女在确诊时即有远处转移。早期患者中,30%~40%可发展为晚期乳腺癌,5 年生存率仅20%,总体中位生存时间为2~3 年。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时间。晚期乳腺癌患者在治疗方案的选择方面有其特殊性,且多线治疗后进展的难治性乳腺癌的治疗缺乏标准推荐。中国乳腺癌诊疗专家共识组对不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后等方面国内外的相关研究数据进行分析、总结和讨论,制订出《中国晚期乳腺癌临床诊疗专家共识(2018 版)》,以供临床医师参考。 

拓展指南:乳腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国晚期乳腺癌临床诊疗专家共识(2018版))] GetToolGuiderByIdResponse(projectId=1, id=d43c71c0016ea6dc, title=中国晚期乳腺癌临床诊疗专家共识(2018版), enTitle=, guiderFrom=中华肿瘤杂志.2018,40(9):703-713., authorId=null, author=, summary=乳腺癌是全球女性最常见的恶性肿瘤,2015 年中国新发乳腺癌病例约27.2 万,死亡约7 万余例。在每年新发乳腺癌病例中,约3% ~ 10%的妇女在确诊时即有远处转移。早期患者中,30%~40%可发展为晚期乳腺癌,5 年生存率仅20%,总体中位生存时间为2~3 年。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时, cover=, journalId=null, articlesId=null, associationId=124, associationName=中国抗癌协会乳腺癌专业委员会, associationIntro=中国抗癌协会是在金显宅、吴桓兴、金家瑞、张天泽、徐光炜、张明和、李光恒、张家庆等教授倡导下,得到当时国家体改委的同意,于1983年6月开始筹备,1984年4月28日正式成立,1985年5月加入中国科协。现在是中国科协主管,中华人民共和国民政部登记注册的国家一级学会。中国抗癌协会的宗旨是:主持肿瘤领域中的学术合作和科学会议;加强国际民间学术交流;全国范围内举办各种学习班、讲习会;培养肿瘤学科技、医务人材;举办学术期刊;动员社会各界力量参与普及和传播肿瘤预防知识。, copyright=0, guiderPublishedTime=Tue Oct 16 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>乳腺癌是全球女性最常见的恶性肿瘤,2015 年中国新发乳腺癌病例约27.2 万,死亡约7 万余例。在每年新发乳腺癌病例中,约3% ~ 10%的妇女在确诊时即有远处转移。早期患者中,30%~40%可发展为晚期乳腺癌,5 年生存率仅20%,总体中位生存时间为2~3 年。晚期乳腺癌目前虽难以治愈,但可通过研发新型治疗药物、优化治疗模式等方法来缓解患者的临床症状,改善患者的生活质量,进一步延长患者的生存时间。晚期乳腺癌患者在治疗方案的选择方面有其特殊性,且多线治疗后进展的难治性乳腺癌的治疗缺乏标准推荐。中国乳腺癌诊疗专家共识组对不可手术的局部晚期和复发或转移性乳腺癌诊断、治疗及预后等方面国内外的相关研究数据进行分析、总结和讨论,制订出《中国晚期乳腺癌临床诊疗专家共识(2018 版)》,以供临床医师参考。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>乳腺癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=4aa0f1c0016689d8" title="2018欧洲共识建议:乳腺癌治疗决策中易感基因的遗传咨询和检测" target=_blank>2018欧洲共识建议:乳腺癌治疗决策中易感基因的遗传咨询和检测</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=70c741c0016592dd" title="NCCN临床实践指南:乳腺癌(2018.V3)" target=_blank>NCCN临床实践指南:乳腺癌(2018.V3)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9cd761c001650078" title="NCCN临床实践指南:乳腺癌(2018.V2)" target=_blank>NCCN临床实践指南:乳腺癌(2018.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=525301c0016a813a" title="NCCN临床实践指南:乳腺癌筛查和诊断(2018.V3)" target=_blank>NCCN临床实践指南:乳腺癌筛查和诊断(2018.V3)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ff75b1c001626a66" title="2018 AGO建议:早期乳腺癌患者的诊断和治疗(更新版)" target=_blank>2018 AGO建议:早期乳腺癌患者的诊断和治疗(更新版)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E4%B9%B3%E8%85%BA%E7%99%8C" target=_blank>有关乳腺癌更多指南</a></ul>, tagList=[TagDto(tagId=3456, tagName=晚期乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12055, appHits=699, showAppHits=0, pcHits=8778, showPcHits=3553, likes=393, shares=28, comments=4, approvalStatus=1, publishedTime=Wed Dec 12 19:51:40 CST 2018, publishedTimeString=2018-10-16, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Dec 12 19:51:40 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 18:16:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国晚期乳腺癌临床诊疗专家共识(2018版))])
中国晚期乳腺癌临床诊疗专家共识(2018版)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=949599, encodeId=b24394959977, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd15451132, createdName=ms2000001577614393, createdTime=Fri Mar 19 22:13:04 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898779, encodeId=953e898e79b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/3360b859ba944059aaffe8a1847ab57b/e91f325d086a40b2b9805211738111d1.jpg, createdBy=b3982392941, createdName=牟德武, createdTime=Thu Nov 12 19:22:01 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355647, encodeId=928635564e88, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/icSRqsIicy1UkicVXxjicQy6fiaF1atibeyGRxvTgUHjiceMQkprf3PFjNgv8IC53ibCibEZ0kicAawOx7KOLIImZMHbgWXw/132, createdBy=dbfc2365831, createdName=熊大猫94, createdTime=Mon Dec 17 10:45:33 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2021-03-19 ms2000001577614393

    学习中

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=949599, encodeId=b24394959977, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd15451132, createdName=ms2000001577614393, createdTime=Fri Mar 19 22:13:04 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898779, encodeId=953e898e79b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/3360b859ba944059aaffe8a1847ab57b/e91f325d086a40b2b9805211738111d1.jpg, createdBy=b3982392941, createdName=牟德武, createdTime=Thu Nov 12 19:22:01 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355647, encodeId=928635564e88, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/icSRqsIicy1UkicVXxjicQy6fiaF1atibeyGRxvTgUHjiceMQkprf3PFjNgv8IC53ibCibEZ0kicAawOx7KOLIImZMHbgWXw/132, createdBy=dbfc2365831, createdName=熊大猫94, createdTime=Mon Dec 17 10:45:33 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2020-11-12 牟德武

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=949599, encodeId=b24394959977, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd15451132, createdName=ms2000001577614393, createdTime=Fri Mar 19 22:13:04 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898779, encodeId=953e898e79b4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/3360b859ba944059aaffe8a1847ab57b/e91f325d086a40b2b9805211738111d1.jpg, createdBy=b3982392941, createdName=牟德武, createdTime=Thu Nov 12 19:22:01 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355647, encodeId=928635564e88, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/icSRqsIicy1UkicVXxjicQy6fiaF1atibeyGRxvTgUHjiceMQkprf3PFjNgv8IC53ibCibEZ0kicAawOx7KOLIImZMHbgWXw/132, createdBy=dbfc2365831, createdName=熊大猫94, createdTime=Mon Dec 17 10:45:33 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2018-12-17 熊大猫94

    点赞

    0